Baseline characteristics of patients stratified according to presence of myocardial infarction and major bleeding
| Characteristics | Neither | MI only | MB only | Both | P value |
| N | 27 109 | 1640 | 1123 | 232 | |
| Female sex | 6454 (23.8%) | 440 (26.8%) | 353 (31.4%) | 87 (37.5%) | <0.001 |
| Age, mean (SD) | 64.3 (11.2) | 66.3 (11.7) | 68.6 (11.1) | 67.7 (11.3) | <0.001 |
| Age >75 | 13 044 (48.1%) | 921 (56.2%) | 723 (64.4%) | 148 (63.8%) | <0.001 |
| Tobacco use | 12 688 (46.8%) | 762 (46.5%) | 427 (38.0%) | 92 (39.7%) | <0.001 |
| Diabetes mellitus | 9357 (34.5%) | 686 (41.8%) | 519 (46.2%) | 133 (57.3%) | <0.001 |
| Hypertension | 17 037 (62.8%) | 1169 (71.3%) | 865 (77.0%) | 191 (82.3%) | <0.001 |
| Dyslipidaemia | 17 313 (63.9%) | 1042 (63.5%) | 691 (61.5%) | 149 (64.2%) | 0.46 |
| Cerebrovascular disease | 2342 (8.6%) | 217 (13.2%) | 163 (14.5%) | 47 (20.3%) | <0.001 |
| Chronic obstructive pulmonary disease | 629 (2.3%) | 72 (4.4%) | 35 (3.1%) | 6 (2.6%) | <0.001 |
| Peripheral artery disease | 309 (1.1%) | 44 (2.7%) | 40 (3.6%) | 15 (6.5%) | <0.001 |
| Prior myocardial infarction | 3281 (12.1%) | 335 (20.4%) | 200 (17.8%) | 58 (25.0%) | <0.001 |
| Prior CABG | 407 (1.5%) | 41 (2.5%) | 19 (1.7%) | 4 (1.7%) | 0.017 |
| Congestive heart failure | 1842 (6.8%) | 258 (15.7%) | 169 (15.0%) | 58 (25.0%) | <0.001 |
| Atrial fibrillation or flutter | 1228 (4.5%) | 124 (7.6%) | 105 (9.3%) | 20 (8.6%) | <0.001 |
| Chronic kidney disease (eGFR <60 mL/min/m2) | 4498 (16.6%) | 475 (29.0%) | 439 (39.1%) | 131 (56.5%) | <0.001 |
| Anaemia at baseline* | 7569 (27.9%) | 638 (38.9%) | 620 (55.2%) | 161 (69.4%) | <0.001 |
| History of cancer | 1246 (4.6%) | 81 (4.9%) | 105 (9.3%) | 18 (7.8%) | <0.001 |
| Acute coronary syndrome | 21 528 (79.4%) | 1406 (85.7%) | 899 (80.1%) | 202 (87.1%) | <0.001 |
| Number of epicardial arteries affected | <0.001 | ||||
| One vessel | 12 451 (45.9%) | 572 (34.9%) | 444 (39.5%) | 60 (25.9%) | |
| Two vessels | 9086 (33.5%) | 562 (34.3%) | 383 (34.1%) | 85 (36.6%) | |
| Three vessels | 5572 (20.6%) | 506 (30.9%) | 296 (26.4%) | 87 (37.5%) | |
| Aspirin on discharge | 26 327 (97.1%) | 1611 (98.2%) | 1101 (98.0%) | 228 (98.3%) | 0.011 |
| P2Y12 inhibitor on discharge | 26 766 (98.7%) | 1626 (99.1%) | 1105 (98.4%) | 230 (99.1%) | 0.31 |
| Potent P2Y12 inhibitor on discharge† | 2995 (11.0%) | 140 (8.5%) | 95 (8.5%) | 16 (6.9%) | <0.001 |
| Anti-coagulation on discharge | 796 (2.9%) | 60 (3.7%) | 86 (7.7%) | 7 (3.0%) | <0.001 |
| Proton pump inhibitor on discharge | 13 209 (48.7%) | 800 (48.8%) | 668 (59.5%) | 124 (53.4%) | <0.001 |
| Duration of DAPT, median (IQR) | 365 (187–401) | 368 (174–505) | 365 (102–403) | 370 (150–535) | <0.001 |
*Anaemia: haemoglobin <13 g/dL for men, <12 g/dL for women.
†Prasugrel or ticagrelor were considered as potent P2Y12 inhibitors.
CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; MB, major bleeding; MI, myocardial infarction.